A photo of Aaron Mochizuki.

Aaron Y. Mochizuki, DO

  • Pediatric Neuro-Oncologist, Division of Oncology
  • Assistant Professor, UC Department of Pediatrics

About

Biography

As a pediatric neuro-oncologist, I treat patients with brain tumors as well as other solid tumors. I seek to provide compassionate care to each person and their family.

The awe-inspiring children going through the most challenging circumstances and their incredible families who support them inspired me to pursue my career.

My research examines how brain tumor immune-cell populations change with therapy and how those changes can predict treatment response.

In my free time, I enjoy running, hiking and snowboarding.

Medical School: A.T. Still University, Mesa, AZ, 2013.

Internship: University of Hawaii, Honolulu, HI, 2014.

Residency: LAC+USC Medical Center, Los Angeles, CA, 2016.

Fellowship: Pediatric Hematology/Oncology, UCLA, Los Angeles, CA, 2019.

Fellowship: Pediatric Neuro-Oncology, Stanford University, Palo Alto, CA, 2021.

Board Certifications: General Pediatrics, 2016; Pediatric Hematology/Oncology, 2021.

Interests

Pediatric neuro-oncology; immunotherapy

Services and Specialties

Brain Tumor Center

Interests

Data science; tumor microenvironment

Research Areas

Oncology

Publications

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Lee, AH; Sun, L; Mochizuki, AY; Reynoso, JG; Orpilla, J; Chow, F; Kienzler, JC; Everson, RG; Nathanson, DA; Bensinger, SJ; et al. Nature Communications. 2021; 12.

IMMU-41. NEOADJUVANT PD-1 BLOCKADE INDUCES T CELL AND CDC1 ACTIVATION BUT FAILS TO OVERCOME THE IMMUNOSUPPRESSIVE TUMOR ASSOCIATED MACROPHAGES IN RECURRENT GLIOBLASTOMA. Lee, A; Sun, L; Mochizuki, A; Reynoso, J; Orpilla, J; Chow, F; Kienzler, J; Everson, R; Nathanson, D; Liau, L; et al. Neuro-Oncology. 2021; 23:vi101-vi101.

A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma. Minturn, JE; Mochizuki, AY; Partap, S; Belasco, JB; Lange, BJ; Li, Y; Phillips, PC; Gibbs, IC; Fisher, PG; Fisher, MJ; et al. Frontiers in Oncology. 2021; 11.

Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Ladomersky, E; Zhai, L; Lauing, KL; Bell, A; Xu, J; Kocherginsky, M; Zhang, B; Wu, JD; Podojil, JR; Platanias, LC; et al. Clinical Cancer Research. 2020; 26:5232-5245.

Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Davidson, TB; Lee, A; Hsu, M; Sedighim, S; Orpilla, J; Treger, J; Mastall, M; Roesch, S; Rapp, C; Galvez, M; et al. Clinical Cancer Research. 2019; 25:1913-1922.

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Cloughesy, TF; Mochizuki, AY; Orpilla, JR; Hugo, W; Lee, AH; Davidson, TB; Wang, AC; Ellingson, BM; Rytlewski, JA; Sanders, CM; et al. Nature Medicine. 2019; 25:477-486.

Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients. Owens, GC; Garcia, AJ; Mochizuki, AY; Chang, JW; Reyes, SD; Salamon, N; Prins, RM; Mathern, GW; Fallah, A. Frontiers in Immunology. 2019; 10.

Precision Medicine in Pediatric Neurooncology: A Review. Mochizuki, AY; Frost, IM; Mastrodimos, MB; Plant, AS; Wang, AC; Moore, TB; Prins, RM; Weiss, PS; Jonas, SJ. ACS Chemical Neuroscience. 2018; 9:11-28.